https://www.selleckchem.com/products/OSI-906.html
ients who are likely to have a response. IMPLICATIONS FOR PRACTICE The BROCADE studies suggest that patients with BRCA mutation benefit from addition of the poly(ADP-ribose) polymerase inhibitor veliparib to carboplatin plus paclitaxel. This study demonstrates that a higher dose of veliparib is tolerable and active in combination with carboplatin alone. With growing interest in imaging-based early response assessment, the authors demonstrate that decrease in [18]fluoro-3'-deoxythymidine positron emission tomography (PET) SUVmax in the f
Like
Comment
Share
